Tempus AI says 13 clinical research abstracts win ESMO 2026 presentation slots

By Public Technologies
  • Tempus AI disclosed 13 cancer research abstracts accepted for ESMO Congress 2026 in Madrid, with presentations scheduled for Oct. 23-27.
  • Results will be presented in the future, using real-world multimodal data to flag clinically meaningful differences in tumor biology, treatment response, outcomes.
  • Readouts span major solid tumors, including prostate cancer, breast cancer, non-small cell lung cancer, ovarian cancer.
  • Program supports precision-oncology biomarker work, patient stratification, clinical-trial design, reinforcing the company’s data and AI product strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001487815) on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk